Cresco Labs (CSE:CL,OTCQX:CRLBF) is planning to further its stake in Nevada and Arizona with a US$282.5 million acquisition of a vertically integrated seed-to-sale cannabis company.

On Monday (September 16), the medical marijuana multi-state operator (MSO) announced it would be adding certain assets of Tryke Companies, including six Reef Dispensary locations in the two states, to its portfolio.


US$252.5 million will go towards Tryke’s operations and the MSO will kick in another US$30 million for the company’s real estate assets.

The transaction is set to close in the first half of 2020 and is subject to state approval from both Nevada and Arizona, among other customary closing conditions.

The deal will be a mix of Cresco Labs shares valued at US$227.5 million, which will be a part of a nine to 21 month lock-up agreement after the deal closes, and US$55 million of cash.

Charlie Bachtell, CEO at Cresco Labs, said in a press release that the move is a part of the company’s second phase of expansion across the country in brands and wholesale distribution.

“With significant in-state populations and tourist traffic, Nevada and Arizona were key near-term targets for expansion,” said Bachtell.

The executive added the transaction would improve efficiencies in Cresco Labs’ portfolio across the US, bringing in high-return projects that are expected to grow over the next few years.

According to the Chicago-based cannabis company, Tryke generated US$70.4 million in revenue in fiscal 2018, cementing itself as one of the biggest private cannabis firms in the US. Bringing in Tryke’s assets is expected to raise Cresco Labs’ market share in Nevada to 8.1 percent, the company added, allowing it to further sales of its line of edibles in the state.

Nevada is one of 11 states in the US where the use of recreational cannabis is legal, having passed legislation to allow adult use of the drug back in 2017. Data from Nevada’s Department of Taxation showed the state’s adult use retail stores and medical dispensaries brought in US$529.9 million in taxable sales during the fiscal 2018 year.

Arizona has its advantages as well. The state has one of the fastest growing patient bases for medical cannabis in the US. As of June 2019, there were over 200,000 qualified patients, according to data from the Arizona Department of Health Services. With the acquisition, Cresco Labs will add an extra 27,000 square feet of cultivation and processing capacity in Phoenix, Arizona.

The deal will also provide Cresco Labs an entry way into the growing cannabis market in Utah, as it gains one of eight cultivation licenses currently awarded in the state. This will add over 160,000 square feet of cultivation, processing and ancillary space in Las Vegas, Nevada.

Tryke’s assets in Las Vegas also include its flagship 4,800 square foot Reef Dispensary store in the Las Vegas Strip. The company said the location had generated US$14.5 million in revenue in the year-to-date period ending August 31, 2019.

In its 2019 Q2 results, Cresco Labs reported a 42 percent revenue increase quarter-over-quarter of US$29.9 million, attributing the growth to strong performances in Pennsylvania and California. However, it also reported net losses at US$3.9 million.

The company is currently dealing with an antitrust review of its C$1.1 billion all-share acquisition of Origin House (CSE:OH,OTCQX:ORHOF), which it first announced in April this year. The deal was set to close in June, but has since been postponed as the Department of Justice takes a second look at the transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Shares of the company dropped to C$9.50 Monday morning as the markets opened, down from its closing price of C$10.50 on Friday (September 13), a decrease in value of 9.5 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less